Age and lymph node status in breast cancer: Not a straightforward relationship

Journal of Clinical Oncology

Volumn 27, Issue 18, 2009, Pages 2900-2901

  Mamounas, Eleftherios P ^a,b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Aultman Health Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROGESTERONE RECEPTOR; TUMOR MARKER;

AGING; AXILLARY LYMPH NODE; BREAST CANCER; CELL PROLIFERATION; CLINICAL ASSESSMENT; DIAGNOSTIC IMAGING; EDITORIAL; HIGH RISK PATIENT; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RISK BENEFIT ANALYSIS; RISK FACTOR; SURGICAL APPROACH; TUMOR VOLUME; AGE; AGED; AXILLA; BREAST TUMOR; FEMALE; LYMPH NODE; NOTE; PATHOLOGY;

AGE FACTORS; AGED; AXILLA; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS;

EID: 67649983328     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.0509     Document Type: Editorial

References (12)

1. Voogd AC, Coebergh JW, Repelaer van Driel OJ, et al: The risk of nodal metastases in breast cancer patients with clinically negative lymph nodes: A population-based analysis. Breast Cancer Res Treat 62:63-69, 2000
2. Van Calster B, Vanden Bempt I, Drijkoningen M, et al: Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: Triple positive tumours are more likely lymph node positive. Breast Cancer Res Treat 113:181-187, 2009
3. Yip CH, Taib NA, Tan GH, et al: Predictors of axillary lymph node metastases in breast cancer: Is there a role for minimal axillary surgery? World J Surg 33:54-57, 2009
4. Laura S, Coombs NJ, Ung O, et al: Tumour size as a predictor of axillary node metastases in patients with breast cancer. ANZ J Surg 76:1002-1006, 2006
5. Haid A, Koberle-Wuhrer R, Knauer M, et al: Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: A comparative evaluation. Breast Cancer Res Treat 73:31-36, 2002
6. Blanchard DK, Donohue JH, Reynolds C, et al: Relapse and morbidity in patients undergoing sentinel lymph node biopsy alone or with axillary dissection for breast cancer. Arch Surg 138:482-487, 2003; discussion 487-488
7. Schrenk P, Rieger R, Shamiyeh A, et al: Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 88:608-614, 2000
8. Goyal A, Douglas-Jones A, Newcombe RG, et al: Predictors of non-sentinel lymph node metastasis in breast cancer patients. Eur J Cancer 40:1731-1737, 2004
9. Katz A, Niemierko A, Gage I, et al: Can axillary dissection be avoided in patients with sentinel lymph node metastasis? J Surg Oncol 93:550-558, 2006
10. Wildiers H, Van Calster B, van de Poll-Franse LV, et al: Relationship between age and axillary lymph node involvement in women with breast cancer. J Clin Oncol 27:2931-2937, 2009
11. Bartlett JM, Ellis IO, Dowsett M, et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 25:4423-4430, 2007
12. Fisher B, Jeong JH, Anderson S, et al: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575, 2002